Deals & IPOs

Windward Bio Raises $225 Million in Nasdaq IPO at $1.69 Billion Valuation

Windward Bio priced its Nasdaq IPO at $17 per share, raising $225 million with a $50 million Sanofi placement, and closed day one valued at $1.69 billion.

By Grace Kim

2 min read

Windward Bio Raises $225 Million In Nasdaq Debut At $1.69 Billion Market Capitalization
Windward Bio Raises $225 Million In Nasdaq Debut At $1.69 Billion Market CapitalizationAI-generated

What's News

  • Windward Bio raised $225 million at $17 per share; day-one market cap hit $1.69 billion on November 13, 2026.
  • Sanofi contributed $50 million through a concurrent private placement.
  • Lead drug WIN378 targets twice-yearly dosing versus monthly for approved rivals; Phase 2 asthma data due H1 2027.
  • Founder Luca Santarelli previously built VectivBio and Therachon, both acquired.
  • Windward has raised $365 million since 2024, including a $200 million Series A in January 2025.

Windward Bio Group priced its Nasdaq IPO at $17 per share and raised $225 million in gross proceeds, closing its first trading day at a market capitalization of roughly $1.69 billion.

The offering, which began trading on the Nasdaq Global Select Market on November 13, 2026, included a $50 million concurrent private placement from Sanofi. Windward sold approximately 10.29 million ordinary shares in the deal.

That's a fast climb for a company that didn't exist three years ago.

Who is behind Windward Bio?

The Basel, Switzerland-based company was founded in 2024 by serial biotechnology entrepreneur Luca Santarelli, M.D., and his team. Santarelli previously helped build VectivBio and Therachon — both of which were ultimately acquired.

Windward has raised $365 million since its formation. That includes a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026. Pivotal bioVenture Partners China invested in every financing round, from early formation through the public listing.

A $1.69 billion market cap on a clinical-stage company with a two-year track record is the punchline here.

What makes WIN378 different?

Windward is developing ultra-long-acting antibody treatments for respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

Its lead program, WIN378, is a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP). The drug is designed for twice-yearly dosing — a sharp contrast with the once-every-four-weeks schedule of currently approved treatments in the category.

The company reported positive interim Phase 2 data in September 2026 supporting twice-yearly dosing of WIN378 in asthma.

WIN378 is currently being evaluated in two trials:

  • The Phase 2/3 POLARIS-1 asthma study
  • The Phase 2 SIRIUS COPD trial

Its pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13, now in Phase 1 development. Global rights outside Greater China and certain Asian markets to both programs were licensed from Chinese biopharmaceutical companies.

Two programs, two trials, one China-licensed backbone — that's the pipeline in plain words.

Where does the $225 million go?

Windward plans to use IPO proceeds to support clinical development of WIN378 and WIN027, advance additional bispecific antibody programs, and fund working capital and general corporate purposes.

The clinical calendar is now the number investors will watch:

  • Top-line Phase 2 asthma data for WIN378: first half of 2027
  • Phase 2 COPD data: second half of 2027
  • Phase 3 asthma data: first half of 2029

What's next?

Sanofi's $50 million placement gives a major pharma player a stake in the story before the pivotal readouts land. If WIN378's twice-yearly dosing holds up in Phase 2 asthma data next year, Windward will head into 2029's Phase 3 results with a differentiated claim in a market built on monthly injections.

By Grace Kim

Source: pulse2.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,178 articles

Related articles

« Previous articleNext article »